Handbook Of Pharmaceutical Excipients 2nd Edition 1994 Direct

Data on how the excipient behaves in formulations.

The second edition of the Handbook of Pharmaceutical Excipients (1994), edited by Ainley Wade and Paul J. Weller, represents a foundational moment in pharmaceutical formulation technology, marking a significant expansion from the inaugural volume to meet the growing demands of drug development in the 1990s. Published jointly by the American Pharmaceutical Association and The Pharmaceutical Press in London, this 651-page hardback established itself as an essential, authoritative resource for industry scientists, providing detailed, systematically organized data on materials that are not merely inactive fillers but crucial components in drug performance. Handbook Of Pharmaceutical Excipients 2nd Edition 1994

Non-proprietary names, synonyms, CAS Registry numbers, chemical structure, and empirical formulas. Data on how the excipient behaves in formulations

A notable observation in a review from the era was that this "weighty tome" was becoming too extensive for print alone, and that future editions would likely require an electronic format. This reflected the rapidly evolving, research-intensive nature of pharmaceutical technology at the time. such as the FDA

This edition was crucial because it signaled a shift in the industry's view of excipients from "inert additives" to critical functional ingredients that require deep characterization.

Beyond the monographs, the 1994 edition provided a substantial suppliers' directory, allowing for ease of sourcing, and two appendices covering laboratory methods to test for the physical properties of these materials.

The 1994 handbook served as a crucial bridge for formulators during a time when regulatory agencies, such as the FDA, were placing higher emphasis on understanding the chemical and physical profiles of excipients. It provided crucial data on material properties like particle size, flowability, and moisture content, which affect the stability and efficacy of the final active pharmaceutical ingredient (API).